US 12,390,156 B1
Identification of metabolites for diagnosis and treatment for sleep apnea
Abdulmohsen Alterki, Dasman (KW); Jehad Ahmed Abubaker, Dasman (KW); Mohamed Abu-Farha, Dasman (KW); and Fahd Al-Mulla, Safat (KW)
Assigned to Sabah Al-Ahmad Center for Giftedness and Creativity, Safat (KW); and Dasman Diabetes Institute, Dasman (KW)
Filed by Sabah Al-Ahmad Center for Giftedness and Creativity, Safat (KW); and Dasman Diabetes Institute, Dasman (KW)
Filed on May 1, 2025, as Appl. No. 19/196,566.
Int. Cl. A61B 5/00 (2006.01); G01N 33/68 (2006.01); G01N 33/92 (2006.01)
CPC A61B 5/4818 (2013.01) [A61B 5/4836 (2013.01); G01N 33/6848 (2013.01); G01N 33/6893 (2013.01); G01N 33/92 (2013.01); G01N 2570/00 (2013.01); G01N 2800/2864 (2013.01)] 13 Claims
OG exemplary drawing
 
1. A method of diagnosing and treating sleep apnea (SA) in a subject, the method comprising:
determining whether the subject needs a Polysomnography by:
obtaining a biological sample from the subject;
performing or having performed on the biological sample mass spectrometry for proteomics and metabolomics analyses to determine if the subject has an altered level of a metabolite selected from the group consisting of PC-O-(38:3), SM (43:1), LPC (24:1), PC (46:1), and TG (44:1), wherein the presence of an altered level of at least one of the metabolites is associated with the presence of SA in a subject;
conducting a Polysomnography on the subject to further determine if the subject has SA; and
treating the subject with a treatment of SA selected from the group consisting of ENT multilevel surgery, continuous positive airway pressure (CPAP) therapy, and bariatric surgery.